Loading company…
Perio Therapia develops periostin-targeting antibody treatments and diagnostic technologies.
Founded in 2017 and based in Suita, Japan, Perio Therapia develops therapies and diagnostics for hard-to-treat diseases, including cancer and inflammatory conditions. Its drug candidates include antibodies targeting pathological periostin in breast cancer. In June 2026, the company raised JPY 1.6 billion in Series D funding, venture debt, and grants from Mitsubishi UFJ Capital, Techno Science, the Japan Agency for Medical Research and Development, and financial institutions.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in